Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $865.72M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 3.97M
Average 2.58M
VSTM Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Verastem, Inc.NASDAQ: VSTM
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses turns positive
Q1 FY2026 other income / expenses was $8.31M, compared with -$7.93M a year earlier. Trailing-twelve-month other income / expenses was -$23.11M.
Context
- Other income / expenses amounted to 127.3% of revenue in FY2025, down 27.7 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near $8.31M or moves back toward the trailing-twelve-month quarterly average of -$5.78M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (39.34M) USD
- Year-over-year change
- -153.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.34M) | -153.9% |
| FY2024 | 2024-12-31 | (15.5M) | -428.5% |
| FY2023 | 2023-12-31 | 4.72M | +639.1% |
| FY2022 | 2022-12-31 | (875K) | +91.1% |
| FY2021 | 2021-12-31 | (9.79M) | — |
Other Income / Expenses vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's LTM Mar 2026 other income / expenses of -$23.11M is the lowest of the 11 companies compared; the peer median is $5.89M.
- Its year-over-year change of -31.1% is the 6th highest of 10, against a peer median of -24.2%.
- Other income / expenses amounts to 46.6% of revenue for VSTM, versus a peer median of 33.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $14.77M | +85.5% | — | — |
| LTM Mar 2026 | $14.69M | +6.7% | +72.3% | — | |
| LTM Jun 2024 | $11.25M | — | -72.8% | 173.3% | |
| LTM Mar 2026 | $10.16M | -24.2% | — | 29.2% | |
| LTM Mar 2026 | $6.34M | -47.8% | -14.5% | 37.9% | |
| LTM Mar 2026 | $5.44M | -67.9% | -1.8% | 19.3% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.09M | -46.1% | +60.9% | — |
| LTM Mar 2026 | $4.79M | +95.0% | +39.6% | — | |
| LTM Mar 2026 | $2.67M | -17.9% | +37.4% | 507.8% | |
| LTM Jun 2026 | -$12.2M | -156.1% | -18.4% | 7.2% | |
| LTM Mar 2026 | -$23.11M | -31.1% | — | 46.6% | |
| Peer median (excluding VSTM) | $5.89M | -24.2% | +17.8% | 33.5% | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.05M | 2.6M | 0 | 10M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 5.3M |
| Gross Profit | 2.05M | 2.6M | 0 | 10M | 25.62M |
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 82.9% |
| Research & Development | 39.35M | 50.56M | 61.36M | 81.33M | 114.6M |
| Selling, General & Admin | 24.12M | 24.98M | 30.73M | 43.62M | 81.15M |
| Operating Expenses | 63.46M | 75.53M | 92.08M | 124.96M | 195.75M |
| Depreciation & Amortization | 72K | 118K | 62K | 26K | 728K |
| EBITDA | (61.16M) | (71.56M) | (83.17M) | (125.86M) | (207.61M) |
| EBITDA Margin | -2978.9% | -2756.4% | — | -1258.6% | -671.6% |
| Operating Income | (61.41M) | (72.94M) | (92.08M) | (114.96M) | (170.13M) |
| Operating Margin | -2991.2% | -2809.6% | — | -1149.6% | -550.3% |
| Interest Income | 181K | 1.22M | 6.21M | 4.15M | 4.07M |
| Interest Expense | 9.97M | 2.14M | 4.14M | 4.56M | 1.14M |
| Other Income / Expenses | (9.79M) | (875K) | 4.72M | (15.5M) | (39.34M) |
| Income Before Tax | (71.2M) | (73.81M) | (87.37M) | (130.45M) | (209.47M) |
| Pre-Tax Margin | -3468.1% | -2843.3% | — | -1304.5% | -677.6% |
| Income Tax Expense | 0 | 0 | 0 | 185K | 0 |
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Net Margin | -3468.1% | -2843.3% | — | -1306.4% | -677.6% |
| EPS (Basic) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| EPS (Diluted) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| Weighted Avg Shares | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
| Weighted Avg Shares (Diluted) | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$6.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.